cystetic Medicines

cystetic Medicines, Inc. is a clinical-stage biotechnology company based in Champaign, Illinois, developing small-molecule anion channels intended to act as "molecular prosthetics" that functionally substitute for missing or dysfunctional CFTR protein channels in people with cystic fibrosis (CF). Its focus is the roughly 10% of the CF population ("the final 10%") whose mutations produce little to no CFTR protein and who therefore cannot benefit from CFTR modulator therapies, a group for which the company states there is no disease-modifying treatment.

The lead program, CM001, is an investigational inhaled dry-powder formulation of amphotericin B, a naturally occurring small molecule already approved to treat fungal infections that self-assembles into ion channels in airway epithelial cell membranes. The stated mechanism is restoration of anion (including bicarbonate) transport independently of CFTR mutation status, addressing the acidic, poorly hydrated airway surface liquid and reduced antimicrobial defense that follow loss of bicarbonate secretion. Preclinical work showed the active ingredient forming CFTR-replacement channels in cultured primary airway epithelia from people with CF not eligible for modulators, and an investigator-initiated proof-of-concept study reported that seven of eight people with CF not on modulators showed decreases in nasal potential difference after nasal administration of the molecular prosthetic.

CM001 is delivered by a portable dry powder inhaler using particle-engineering technologies the company says have already been used in existing cystic fibrosis treatments, which it presents as a basis for commercial-scale manufacturing. The company frames its broader goal as one simple, broadly accessible therapy that could ultimately benefit all people with CF, not only the final 10%.